Penumbra Q4 revenue $284.7M (+28.7%); thrombectomy sales up 42.4%

Penumbra Inc

2023-FY EPS reported $2.32 revenue$1,058,522,000

Revenue of $284.7M in Q4 2023, up 28.7% YoY; full-year $1,058.5M, up 25.0%.
Thrombectomy product revenue $190.8M in Q4 (+42.4%); full-year $677.3M (+32.5%).
Net income $54.2M in Q4; adjusted EBITDA margin 18.8%; cash and investments up $40.3M.
FY 2024 guidance: total revenue growth 16-20%, US thrombectomy growth 27-30%, gross margin +100-150bps.
Non-GAAP operating income $37.4M in Q4; full-year $101.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Penumbra Inc reported the fourth quarter and full year ended December 31, 2023 results: revenue $284.7 million, net income $54.2 million. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $284.7 million
Net income: $54.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: • Revenue of $284.7 million for the fourth quarter of 2023, an increase of 28.7% or 27.9% in constant currency 1 compared to the fourth quarter of 2022. Revenue of $1,058.5 million for the full year 2023,

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0001321732-24-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.